The PMDA (Japan’s Pharmaceuticals and Medical Devices Agency) and FDA (US Food and Drug Administration) approval processes differ in review timelines, clinical data requirements, submission formats, and post-approval obligations. Both agencies apply rigorous scientific standards, but their regulatory frameworks reflect distinct national health systems, patient population considerations, and procedural traditions. Understanding these differences is essential for companies planning multi-regional market entry strategies. To learn more about how we support clients through these processes, visit our regulatory affairs services.
How do PMDA and FDA review timelines compare?
The PMDA typically completes its standard review within 12 months for priority products and within around 12 to 17 months for standard applications, measured from filing acceptance. The FDA’s standard review target is 12 months (PDUFA goal), with a 6-month priority review for serious conditions. In practice, total approval timelines can be comparable, but the two agencies reach those timelines through very different procedural structures.
A key distinction is that the PMDA conducts a highly interactive review process. Applicants engage in formal consultations at multiple stages before and during review, which reduces the likelihood of major deficiencies at the end of the process. The FDA, by contrast, relies more heavily on a single complete response cycle, where major questions are consolidated and issued after the review period closes. This means that while FDA timelines can be shorter when an application is clean, a Complete Response Letter can add significant time if gaps are identified.
Japan also requires a pre-approval inspection of manufacturing facilities, which is coordinated by the PMDA and can affect the overall timeline depending on scheduling and GMP compliance status.
What types of clinical data does each agency require?
Both the PMDA and FDA require evidence of safety, efficacy, and quality from well-controlled clinical trials, but the PMDA places particular emphasis on data generated in Japanese patients. Historically, Japan required locally conducted bridging studies or full domestic trials to confirm that foreign clinical data is applicable to the Japanese population. This requirement has evolved, but ethnic sensitivity data remains a significant consideration.
The FDA accepts global multi-regional clinical trial data without a domestic-specific requirement, provided the study design and statistical analysis meet its standards. It does expect that the enrolled population reflects diversity relevant to the intended US indication, but this is not tied to national ethnicity in the same way.
The PMDA’s approach to bridging is guided by ICH E5 principles, which assess whether intrinsic and extrinsic ethnic factors could affect the drug’s clinical profile in Japanese patients. Companies developing global programs must plan for this early, either by including Japanese sites in pivotal trials or by designing dedicated bridging studies. The FDA does not apply an equivalent ethnicity-based bridging requirement, though it does scrutinize subgroup analyses carefully.
How does the submission format differ between PMDA and FDA?
Both agencies accept submissions in the Common Technical Document (CTD) format, which standardizes the structure of pharmaceutical dossiers globally under ICH guidelines. However, the PMDA requires that the CTD overview and summary sections be submitted in Japanese, while the full technical data modules can be in English. The FDA accepts submissions entirely in English.
Beyond language, the PMDA requires submission through a licensed Marketing Authorization Holder (MAH) established in Japan. Foreign companies cannot apply directly and must either establish a local entity or partner with a Japanese MAH. The FDA allows direct applications from the drug developer regardless of where the company is headquartered.
The PMDA also uses an electronic submission gateway (eCTD) with specific regional requirements for file format and naming conventions that differ slightly from the FDA’s eCTD specifications. Companies should validate their submission packages against each agency’s technical guidance before filing to avoid administrative rejections.
What are the main regulatory pathways for accelerated approval?
Both the PMDA and FDA offer accelerated pathways for products that address serious unmet medical needs, but the pathway names and specific criteria differ. The FDA offers four main expedited programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review. The PMDA offers Priority Review, Sakigake Designation, and Conditional Early Approval as its primary mechanisms for faster access.
FDA accelerated pathways
Breakthrough Therapy Designation is particularly valuable because it enables intensive FDA guidance throughout development, not just a faster review clock. Accelerated Approval allows the FDA to approve a drug based on a surrogate endpoint reasonably likely to predict clinical benefit, with post-marketing confirmatory trials required. Fast Track facilitates rolling review, meaning the FDA can evaluate completed sections of the application before the full dossier is submitted.
PMDA accelerated pathways
Japan’s Sakigake Designation was introduced to encourage the development of innovative drugs and medical devices in Japan first. It provides priority consultations, accelerated review (target of 6 months), and aims to make Japan one of the first countries to approve a product. Conditional Early Approval applies to products for serious diseases where surrogate endpoints or limited trial data are accepted, with confirmatory evidence required after approval. This is conceptually similar to the FDA’s Accelerated Approval but operates under Japan’s specific regulatory framework.
How do post-approval obligations differ between PMDA and FDA?
Post-approval requirements are generally more extensive under the PMDA than the FDA, particularly regarding re-examination and re-evaluation periods. Japan mandates a re-examination period of typically 6 to 10 years for new active substances, during which the MAH must collect and submit post-marketing safety and efficacy data. At the end of this period, the PMDA formally re-evaluates the product’s approval. The FDA does not have a directly equivalent mandatory re-examination system.
Both agencies require pharmacovigilance, periodic safety reporting, and Risk Management Plans (or Risk Evaluation and Mitigation Strategies in the US). Japan’s Risk Management Plan requirements are detailed and must be submitted as part of the initial application, with updates required throughout the product lifecycle.
The PMDA also conducts post-marketing inspections of manufacturing sites on a regular cycle, and any changes to manufacturing processes or facilities require prior approval or notification depending on the change category. The FDA’s change management framework under post-approval supplements follows a comparable tiered structure, but the specific thresholds and timelines differ.
Should companies pursue PMDA and FDA approval simultaneously?
Pursuing PMDA and FDA approval simultaneously is strategically viable and increasingly common for products with global market potential, but it requires careful upfront planning. The two processes can run in parallel if the development program is designed to satisfy both agencies from the start, particularly regarding clinical data requirements and manufacturing standards.
The main challenge is aligning the clinical program to meet Japan’s bridging data expectations while also satisfying FDA requirements for the same pivotal trials. Including Japanese patient sites in global multi-regional clinical trials is the most efficient approach, as it generates data acceptable to both agencies without running separate studies. Companies should also plan for the Japanese MAH requirement early, as establishing or contracting a local entity takes time. Our team has the experience to guide you through this process — find out more on our company page.
From a timeline perspective, simultaneous submissions do not guarantee simultaneous approvals. The PMDA and FDA have independent review clocks, and one agency may request additional data that delays its decision independently of the other. Building parallel regulatory project plans with distinct milestones for each agency helps manage this complexity without creating bottlenecks that affect both submissions.
How Starodub Supports PMDA and FDA Regulatory Strategy
Navigating two of the world’s most demanding regulatory frameworks at the same time requires more than procedural knowledge. It requires a regulatory strategy that is built into the development program from day one. At Starodub, we help biopharmaceutical and medical device companies design and execute regulatory strategies that work across multiple jurisdictions, including Japan and the United States.
Our support for PMDA and FDA regulatory programs includes:
- Regulatory pathway assessment and gap analysis for both PMDA and FDA requirements
- Clinical development planning that addresses Japanese bridging data expectations and FDA evidentiary standards simultaneously
- CTD dossier preparation and review, including Japanese-language module requirements for PMDA submissions
- Advice on accelerated designation strategies, including Sakigake, Breakthrough Therapy, and Priority Review eligibility
- Post-approval lifecycle management, including re-examination planning for Japan and post-marketing commitments for the FDA
- Coordination with Japanese MAH partners and manufacturing site readiness for pre-approval inspections
With over 400 completed projects and more than 300 clients supported, we bring the depth of experience needed to keep complex multi-regional programs on track. If you are planning a parallel PMDA and FDA submission or need a regulatory strategy review, contact Starodub today to speak with one of our regulatory affairs specialists.
Related Articles
- What is the difference between GMP compliance and GMP certification?
- What is regulatory strategy governance and how do you implement it?
- What is the average time to approve a drug?
- What regulatory pathway should startups choose for first medical device approval?
- How does software as medical device (SaMD) regulation work?
